Podcasts about Genoa

Andrew, Irfan, and Jae discuss Inter's loss to Liverpool and away win to Genoa. They also preview the Supercoppa.

Il nostro commento alla sfida tra Genoa e Inter di ieri pomeriggio. Sconfitta per i rossoblù, che non ottengono punti ma che lascia sensazioni positive per il proseguo della stagione. Buoncalcioatutti!

Scarica Revolut gratis con il mio link per ricevere un bonus di benvenuto di €20*: https://get.revolut.com/e9Jc/podcast1*Si applicano condizioni minimeEnrico Zambruno e Giovanni Esposito raccontano le cinque partite di questa incredibile domenica di Serie A.Potrero, dove tutto ha inizio. Un podcast sul calcio italiano e internazionale.Su Como TV (https://tv.comofootball.com) nel 2025 potete seguire in diretta e gratuitamente le partite della Saudi Pro League, Saudi King's Cup, Supercoppa d'Arabia, Copa Libertadores, Copa Sudamericana, Recopa, Liga Profesional Argentina, Trofeo de Campeones argentino, Eredivisie, Coppa di Francia, Scottish Premiership, Coppa di Scozia, Scottish League Cup, Scottish Championship, Coppa di Portogallo, Supercoppa di Portogallo, HNL croata e tutti i contenuti di calcio italiano e internazionale on demand.Diventa un supporter di questo podcast: https://www.spreaker.com/podcast/potrero--5761582/support.

Nessuno sembra voler rimanere in vetta alla Serie A e la dimostrazione arriva da Milan e Napoli che si fermano rispettivamente con Sassuolo e Udinese. A sfruttare l'occasione è l'Inter che batte il Genoa e sale così al comando del campionato.

Audra and Holden’s secret revealed; Sienna and Matt come to GC; Cane and Lily plan a not-date, then Cane and Phyllis kiss!; Michael and Lauren’s 20th Anniversary; and Victor vs. Jack 2025! Visit https://www.yrchat.com to chat with fun and friendly fans of The Young and the Restless. THIS WEEK: Ali’s Y&R Recap, The Weekly Y&R […]

Scarica Revolut gratis con il mio link per ricevere un bonus di benvenuto di €20*: https://get.revolut.com/e9Jc/podcast1*Si applicano condizioni minimeScamacca super e la Dea vince, Lazio che colpo in 9! Oggi c'è Bologna-JuveScamacca super con una doppietta e l'Atalanta batte un Cagliari da applausi. La Lazio in 9 batte il Parma grazie alla rete di Noslin, mentre il Torino vince contro la Cremonese tra proteste nel finale. Oggi in campo Milan, Napoli e Inter, mentre la sera c'è il big match Bologna-Juventus. Ne parlano Simone Indovino e Roberto Ugliono.Potrero, dove tutto ha inizio. Un podcast sul calcio italiano e internazionale.Su Como TV (https://tv.comofootball.com) nel 2025 potete seguire in diretta e gratuitamente le partite della Saudi Pro League, Saudi King's Cup, Supercoppa d'Arabia, Copa Libertadores, Copa Sudamericana, Recopa, Liga Profesional Argentina, Trofeo de Campeones argentino, Eredivisie, Coppa di Francia, Scottish Premiership, Coppa di Scozia, Scottish League Cup, Scottish Championship, Coppa di Portogallo, Supercoppa di Portogallo, HNL croata e tutti i contenuti di calcio italiano e internazionale on demand.Diventa un supporter di questo podcast: https://www.spreaker.com/podcast/potrero--5761582/support.

Post-partita Genoa-Inter 1-2, 14 dicembre 2025. Gol Bisseck, gol Lautaro Martinez, gol Vitinha.

Le parole di Chivu alla vigilia di Genoa-Inter, con il punto sugli infortuni e qualche risposta alle polemiche della settimana.

La lista convocati per la sfida contro l'Inter conferma, in casa Genoa, due recuperi come quelli di Frendrup e Grønbæk. Si fermano, però, Messias e Cuenca. Le ultime a 24 ore dalla sfida coli nerazzurri. Buoncalcioatutti!

Vigilia di Genoa-Inter con le parole di Chivu in conferenza, le possibili scelte per la sfida al Marassi e la bomba di mercato che vede protagonista Davide Frattesi!

Ampio spazio alle parole di mister De Rossi a due giorni dalla sfida tra Genoa e Inter. Parliamo di quanto emerso in conferenza stampa nella puntata odierna. Buoncalcioatutti!

After more than four decades in professional kitchens—including twenty years as chef-owner of Portland's beloved Nostrana—Cathy Whims has published her first cookbook. The Italian Summer Kitchen captures the essence of Italian summer cooking through the lens of the Pacific Northwest, featuring simple, ingredient-driven recipes and beautiful watercolor illustrations.This conversation was recorded in Bologna, Italy, at Sette Tavoli, one of Brian's favorite restaurants. We discuss Cathy's journey from vegetarian teenager to celebrated chef, her time training with Marcella Hazan and Dario Cecchini, the cult following around Nostrana's signature Insalata Nostrana, and how the pandemic changed her approach to this book.In this episode:• Growing up cooking with Julia Child cookbooks• Working through every station at Genoa, Portland's premier fine dining restaurant• The pivotal trips to Italy that changed everything• Opening Nostrana and celebrating 20 years this year• Training with Marcella Hazan and the tomato butter sauce that's been on the menu since day one• The secret to the perfect radicchio salad• Why she chose watercolor illustrations over photographs• How COVID-19 shifted the book from restaurant cooking to home cooking• The "less is more" philosophy of cucina povera• An ingredient challenge gamePlus, on our Substack: Two recipes from the book—Spaghettini with Prawns and Yogurt Panna Cotta—and hear Cathy read an excerpt from The Italian Summer Kitchen.Special thanks to Jaqueline and the team at Sette Tavoli in Bologna for hosting this recording.Guest Cathy WhimsBook The Italian Summer Kitchen by Cathy WhimsEpisode Length 45:28Timestamps00:00 - Introduction & recording in Bologna02:15 - Growing up in Chapel Hill, NC04:30 - The vegetarian awakening and her mother's response07:45 - Latin major turned professional cook10:20 - Landing the dream job at Genoa12:45 - Working through every station15:30 - The trips to Italy that changed everything18:00 - "The hundred dollar chicken" and knowing it was time to move on21:00 - Opening Nostrana: a new vision23:30 - Training with Marcella Hazan26:15 - The Insalata Nostrana: origin story and technique30:45 - The ice water secret33:00 - Other influential cookbook authors35:30 - The pandemic pivot: from restaurant book to home cooking39:00 - Why illustrations instead of photographs42:15 - Summer preservation techniques45:00 - The ingredient challenge game45:30 - Challenge #1: Seafood (spot prawns, bottarga, zucchini blossoms, truffle butter)49:15 - Challenge #2: Agrodolce (hazelnuts, red wine vinegar, peaches, marshmallows)53:00 - Challenge #3: Tuscan Crossover (chanterelles, guanciale, ricotta, kimchi)57:30 - ClosingCreditsHost: Brian Hogan StewartRecorded at: Sette Tavoli, Bologna, ItalySalt + Spine is part of the Heritage Radio Network. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit saltandspine.substack.com/subscribe

Guests Dr. Andrea Necchi, Dr. Ashish Kamat and host Dr. Davide Soldato discuss JCO article "End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer," focusing on the evolving treatment landscape of MIBC (muscle-invasive bladder cancer) and the need to properly design novel trials investigating non-operative management while including the incorporation of biomarkers and patient perspectives in clinical trials. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today we are joined by JCO authors Andrea Necchi, Associate Professor of Medical Oncology at University San Raffaele and Medical Oncology at Ospedale San Raffaele in Milan, Italy, and Ashish Kamat, Professor of Urologic Oncology and Cancer Research at University of Texas MD Anderson Cancer Center. Both Professor Necchi and Professor Kamat are internationally recognized experts in the field of genitourinary malignancy and particularly in bladder cancer. Today we will be discussing the article titled "Endpoints for the Next Generation Bladder-Sparing Perioperative Trials for Patients with Muscle-Invasive Bladder Cancer." So thank you for speaking with us, Professor Necchi and Professor Kamat. Dr. Andrea Necchi: Thank you, Davide, and thank you JCO for the opportunity. Dr. Ashish Kamat: Yeah, absolutely. It is a great honor and privilege to be discussing this very important article with you. So thank you for the invitation. Dr. Davide Soldato: The article that you just published in JCO reports the results of a consensus meeting that was held among experts in the field of genitourinary malignancy and particularly for bladder cancer. So the objective was really to define endpoints for a novel generation of trials among patients diagnosed with muscle-invasive bladder cancer. So my first question would be: what is the change in clinical practice and in clinical evidence that we have right now that prompted the start of such consensus in 2025? Dr. Andrea Necchi: So, we are living so many changes in the treatment paradigm of patients with muscle-invasive bladder cancer. In general, patients diagnosed with bladder cancer or urothelial cancer today, thanks to the advent of immunotherapy or immunotherapy combinations, and today thanks to the advent of novel antibody-drug conjugates like enfortumab vedotin in combination with immunotherapy that are actually changing the landscape of treatment of patients with metastatic disease and also are entering quite fast into the treatment paradigm of patients with organ-confined disease with a lot of clinical trials testing these combination therapies, neoadjuvantly or adjuvantly, before or after radical cystectomy. Having said that, by potentiating the efficacy of systemic therapy, an increasing number of patients that receive neoadjuvant therapy of any kind, at a certain point in time, result to have achieved a deep response to systemic therapy, evaluated radiologically with conventional imaging, CT scan or MRI, or with cystoscopy or with other urology-based techniques, urinary cytology, and so. And based on the fact that they achieve a complete response, so no residual viable disease after systemic therapy, they raise concern about the fact that they have to undergo surgery like radical cystectomy that is quite impactful for their quality of life and for the future of their lives after the surgery. So the point that the patients are raising, and the patients are raising this point, is primarily due to the efficacy of systemic therapy. And we have seen so many cases fortunately achieving a deep response. So the question about what to do with the patient that at a certain point, at the start with the commitment to radical cystectomy, but at a certain point in time change their mind towards something else if possible, depending on the fact that they have achieved a deep response, is something that is a question and is a need to which we have to provide data, information, and guidance in general to the patients. Dr. Davide Soldato: If we look at the population that the recommendations were formulated for, we are mainly speaking about patients who would be fit for cystectomy, and this is a very distinct population compared to those who are not fit for cystectomy, both from a medical oncology point of view but also from a urologic point of view in terms of surgery. So, can you explain a little bit to our listeners why you think that this distinction is critical and why you developed this recommendation especially for this population? Dr. Ashish Kamat: That is a very important distinction that you made. To build upon what Professor Necchi mentioned earlier, this question that we get from patients after neoadjuvant therapy or systemic therapy is not a new question. It has been something that they have been asking us for the last 20 or 30 years. "Do I really need to have my bladder taken out?" And patients who are especially not fit for surgery will sometimes say, "Do I need to have my bladder taken out? And if I cannot have my bladder taken out, am I going to just not have anything done?" Because the eligibility for radical cystectomy is also a moving target. Over the years with improvement in surgical technique, improvement in perioperative therapy, ERAS protocols, et cetera, it is really unusual for us to deny a patient the opportunity to have major surgery unless clearly they have very significant comorbid conditions. So I think this endeavor is more broadly encompassing of the patient population than what was evident in previous years. And I really want to give a shout out to Professor Necchi because what we did was, as part of the International Bladder Cancer Group and Professor Necchi is an integral part of the scientific advisory board, we broached this topic broadly during one of our discussions. And of course, Andrea always does this, he picks on a topic and then he says, "Okay, we need to discuss this really in detail," put together a multinational, multicenter collaborative group, but the driving force was our patients. Because our patients are constantly asking, "Do I need to lose my organ? Do I need to have radiation therapy?" which again, also, has a lot of side effects. So this was really to answer the question in today's day and age as to do we need to do local consolidation, and if so, in what way? It is not a new question, but we have newer therapies, newer technology, and better ways to answer this. So it is a much needed question that needs to be answered. And I think the distinction between non-surgical candidates and surgical candidates is a little bit blurred in today's day and age. Dr. Davide Soldato: What about the eligibility, for example, for cisplatin-based chemotherapy? Because I think that that is a very fundamental part of this type of strategy that we apply to patients with muscle-invasive bladder cancer. So we know that there are some caveats for proposing such treatment. And also this population was specifically defined inside this recommendation. Dr. Andrea Necchi: I think that the focus of our work is just to analyze what is happening after any type of systemic therapy the patient may get neoadjuvantly. So it is not actually a question of treatment eligibility or including cisplatin eligibility. This is an old question of today's practice and clinical trials. But regardless of what the patient received neoadjuvantly, the point that we have addressed in our consensus meeting was what to do next as a further step after systemic therapy or not. So basically we are- the consensus guidance includes all-comers, so patients to get any type of systemic therapy. So really non-selected based on specific features that determine a special eligibility to a special or a particular therapy. But an all-comer approach is always the winning approach for the translation to be in practice, an all-comer approach just focusing on what has happened after treatment and that we are assessing by the use of conventional imaging, MRI or CT, cystoscopy, urinary cytology, and trying to merge all together this information, all these features in a unique, shared, reliable definition of clinical complete response that could be used as a biomarker for the selection of newer therapies instead of pathological response that has been historically used, and maybe surrogate for the outcome, the long-term outcome and survival of these patients. Dr. Davide Soldato: A very specific point of the consensus was actually the definition of clinical complete response. As you were saying, this is actually a combination of several parameters including urinary cytology, the use of cross-sectional imaging, for example CT scan, but also the evaluation in cystoscopy of the bladder. Do you foresee any potential problems when applying this type of recommendation, not inside clinical trials, but in the context of routine clinical practice? Dr. Ashish Kamat: Absolutely. And that was the whole reason we had this consensus meeting. What happens nowadays in daily practice, and we see this every day at our center, we see patients referred to us. This definition or this sort of attempt to define clinical complete response is an ongoing issue. And urologists, medical oncologists, radiation oncologists are always looking to see, does my patient have a complete response? That definition and those paradigms have changed and evolved over the years. The FDA had a workshop many years ago looking at this very question. And it was to address the proposal that complete clinical response, which is a clinical definition, a clinical state, does this correlate with pathologic response? And with the technology and the systemic therapies we had then, the answer was 'no'. In fact, more patients got recurrent disease than did not get recurrent disease. And that is why, of course in the paper we mention the trials that looked at this question, the trials that evolved around this question. And I think the distinction between a clinical trial and daily practice is extremely important when we are looking at this definition per se. Because essentially what happens with this issue is that if the patient is not appropriately counseled, and if the physician does not do the appropriate clinical complete response assessment as Professor Necchi mentioned, right, cystoscopy, cytology, imaging, use of markers that are still in evolvement, we risk doing harm to the patient. So we caution in the paper too that this definition is not ready for prime time use. It is something that needs to be studied. It is a rigorous definition and currently we are recommending it for clinical trials. I am sure eventually it will trickle down into clinical practice, but that guidance was not the purpose of this consensus meeting. Dr. Davide Soldato: There are several parameters that are potentially evolving and could potentially enter inside of clinical practice. For example, you mentioned pelvic MRI and we have now very specific criteria, the VI-RADS criteria, we're able actually to diagnose and also to provide information. So along with these novel imaging techniques, we also know that there are novel biomarkers that could be explored, for example ctDNA and urinary DNA. So what I was wondering is, why were not these included inside the definition that you provide for clinical complete response? And do you think that, as we are designing these trials to potentially spare cystectomy for this patient, we should include these biomarkers very early so that we can actually provide better stratification for our patients and really propose this type of cystectomy-sparing strategy only to those where we are very confident that we have obtained a clinical complete response? Dr. Andrea Necchi: I would say you have just to wait. So a follow-up is ongoing and hard work is ongoing. At the time we met, at the time we established the meeting in mid-December last year, we had no information on the ctDNA data from major trials, with only a few exceptions. So we were just at the beginning of a story that was more than likely to change but still without numbers and without data from clinical trials. Now in just nine months or 10 months time, we have accumulated important data and newer data will be presented during just a few weeks and a few days regarding the ctDNA, circulating tumor DNA in particular, as a prognostic marker assessed baseline or assessed after neoadjuvant therapy. So the point is certainly well made and ctDNA is certainly well shaped to be incorporated in a future definition of clinical complete response. But you have to consider the fact that most of the data that we are accumulating related to ctDNA are about the post-cystectomy field or the metastatic field. So regarding neoadjuvant therapy, you know, we have neoadjuvant therapy in the context of bladder-sparing approach, basically we have no information. And the point that is emerging in our daily practice when using these biomarkers or in clinical trials, and the impression in general, is that it is a very strong biomarker associated with survival, but we absolutely do not know what is the performance of the test in the prediction of superficial bladder relapses, high-grade pTa relapse in the bladder that is left untouched in the patient. We are considering, and maybe it will be just a matter of further discussion, not just what is happening within the immediate endpoint of clinical CR, but also what is happening later with other survival endpoints. And for example, when looking at the type of events that we may see in this kind of bladder-sparing approaches, most of the events, also in the trials that have been published including the RETAIN study published in JCO, most of the events are related to superficial high-grade superficial non-muscle invasive relapses. So the ability to predict these types of events with ctDNA is completely unknown. Maybe, maybe other liquid biomarkers like urinary tumor DNA, utDNA, could be a bit better shaped in the prediction of this kind of events, you know. But we have still to build the story. So the question is good. The answer is yes, we will likely, more than likely incorporate liquid biomarkers in the definition, but we have to wait at least more data and more robust data in order to translate this information in routine practice, you know. Another consensus meeting is organized by IBCG and the same folks for November. This meeting will be primarily focused on the liquid biomarkers, the interpretation and use and approval and so of liquid biomarkers including bladder cancer. And we will likely be able to address all these, most of these open issues, so most of these points in the next meetings. Dr. Davide Soldato: In the consensus you say that probably clinical complete response is now ready to be included in early phase trials, so actually to test what is the efficacy of the regimens that is being evaluated inside of these trials. But you actually do very in-depth work of defining what are the most appropriate endpoints for later phase trials. So to be very specific, the phase three registrational trials that bring new regimens inside of this space. So I just wanted to hear a little bit about what was the definition for event-free survival, which you define as the most appropriate one for this type of trials. And as you were mentioning before, Professor Necchi, there is a very specific interest on the type of events that we observe, especially when we look at these superficial relapses inside of the bladder. So was this a very urgent matter of debate as we define which type of events should actually trigger event-free survival? And did you make a very thoughtful decision about why using this type of endpoint instead of others, for example metastasis-free survival? Dr. Ashish Kamat: Yeah, this was a matter of intense debate as you might imagine. And again, this is a moving target. So as Professor Necchi mentioned, we tend to partner with each other, our organizations, on having definitions of clinical complete response, biomarker, retreats, and then using that as a marker, and you might imagine this definition of what is appropriate event-free survival, what events matter to the patient, is something we have been talking about for two years. It was not just something that came up at the retreat. But at the retreat there was intense discussion. One of the things that we talked about was bladder-intact event-free survival because we are trying to spare the patient's bladder. And do we count bladder-intact event-free survival as something that is relevant? The patient advocates absolutely liked that, right? They wanted that. But then we also learned from some of the studies, for example from the RETAIN study, that the non-muscle invasive recurrences can actually lead to metastatic disease. It is not as benign when you have a patient with muscle-invasive bladder cancer that then develops a non-invasive tumor because maybe there is cancer growing underneath the surface that we don't detect when we look in the bladder. So a lot of those discussions were held, debated. It was a consensus. I have to say it was not 100% agreement on that particular definition, but it was broad consensus. And Andrea, do you want to clarify a little bit as to how we came about that consensus? Because I think this is a very important point we need to make. Dr. Andrea Necchi: We focused on a bit different definition of BI-EFS, Bladder-Intact Event-Free survival. Just stating EFS as an all-inclusive parameter including all type of high-grade relapse or progression or death that may happen to the patient. So that we were counting high-grade pTa, pT1, CIS relapses to the bladder and of course more deeper involvement in the muscle layer and so, and metastatic disease as a relapse. But the point is that as compared to the classical bladder-intact EFS definition of chemoradiation bladder-sparing approaches that is including muscle-invasive relapses only or death as events, we tried to be as inclusive as possible in order to be as much conservative as possible and to raise as higher the bar as possible for the success. And this is actually what the patients are asking us. So they are asking, "Okay, I can save my bladder, sparing radical cystectomy, but at which cost?" So in order to provide an answer, we have to be very, very cautious and be on the right shape, on the right position to say, "Okay, we have accomplished the most, the safest points, you know, by which you can proceed with the bladder-sparing." This is the first point. The other point is related to the MFS, metastasis-free survival that you have mentioned. For sure, it was recognized as a very important point for sure. But in the discussion was clear that our focus was in saving patients, curing the patient, and saving the bladder. Any single event, superficial event that may occur in the bladder-saving approaches of this kind may expose the patient to an extra risk of developing distant metastases, as it happened for example in the RETAIN study. So EFS defined as we have agreed and published, is actually a way of including or anticipating in a safest position the MFS. Because most or if not the entirety of the events of metastasis development in patients undergoing bladder-sparing after neoadjuvant systemic therapy were preceded by a superficial phase of disease relapse, you know. So I remember very, very few, or we can count just on the finger of one hand, the cases that have been reported in the literature developing de novo metastatic disease in the similar bladder-sparing approaches, in particular when using a maintenance immunotherapy strategy, you know, after they reach TURBT. So this is the reason why with all the limitation that Ashish has mentioned, with all the uncertainties that are still there, the nervousness that is still there, EFS, as defined in the protocol, as put in the paper, is to us at the moment is the safest way to use a primary endpoint in potentially registration trials of this kind with perioperative systemic therapy and response-adapted surgery. Dr. Ashish Kamat: And David, just to be absolutely clear for our listeners, right, so what was the event-free survival that we defined? Essentially it was a very inclusive definition. Event was defined as high-grade tumor persistence, recurrence, or progression during or after perioperative therapy, and receipt of any additional standard of care treatment including radical cystectomy, radiotherapy or even intravesical therapy. So this was done at the behest of our patient advocates because we really wanted to make a very robust definition that could be utilized appropriately as an adequate primary endpoint for both early and late phase bladder preservation trials. Dr. Davide Soldato: I think that it really highlights one of the points that I liked the most about this consensus is that it really incorporated the patient vision and a sort of shared decision making process when we are deciding how we want to design these trials that will explore this bladder-sparing surgery. And Professor Necchi mentioned something that I think will be also a very interesting question for trials that will be developed considering the activity of this combination that we are seeing right now, which is maintenance. Because right now our approach in the few cases where patients do not do any type of treatments after an induction with neoadjuvant treatments is basically represented by observation. So I was wondering if you think that the field will actually evolve to a sort of maintenance strategy even in patients that will achieve a complete clinical response? Dr. Andrea Necchi: We just mentioned briefly in the paper, this is a very important point that was touched during the discussion, and in particular was raised and discussed by FDA people participating in the meeting. And when looking at the data from the trials that were available and are still available thus far, we could provide a suggestion that maintenance immune therapy is the preferred approach in this kind of approach as it currently stands, as the data currently stand. Because the cleanest data towards the successful part of this journey is related to the studies that provided a kind of maintenance therapy, like the study with nivolumab or the RETAIN-2 study with maintenance immune therapy instead of RETAIN study that was just stopping treatment until surgery with MVAC chemotherapy. So in general the impression is that maintenance therapy may help in reducing the type of events, including the events that we incorporate in the EFS definition that we mentioned in the paper. The point that you mentioned is very important because on the other side we have a problem, a big problem of affordability and cost of the treatment. The de-escalation trials are an urgent need and represent a call for the studies. Unfortunately, as you mentioned, this is something that moves beyond the possibilities of this type of consensus because we don't have data and we have to accumulate data from clinical trials prior to saying, "Okay, certain patients could de-escalate therapy and stop therapy and some other not." So we are still at the very beginning. So we can do- we can discuss about this in the radical cystectomy paradigm but not in the bladder-sparing paradigm, you know. But this is for sure a point, a discussion point that will be taken, pretty well taken in one year or two year projection. Dr. Davide Soldato: I was wondering if in the consensus, considering that patient advocates and patient associations were also involved, did you decide to actually suggest the inclusion of patient-reported outcomes or the evaluation of shared decision-making in the development of this trial really as endpoints that should matter as much or as much as possible as event-free survival and clinical complete response? Dr. Ashish Kamat: Oh yeah, absolutely. We had patient advocates, we had the World Bladder Cancer Patient Coalition, Bladder Cancer Advocacy Network, patient representatives. And we always consider this. Shared decision-making is actually the impetus behind why these efforts have been launched, right? So it is the shared decision-making that is very, very important. It is the driving force behind what we do. And it is worth noting, for example, for the design of such studies, regulatory agencies consider response-based endpoints or overall survival as primary endpoints. But the patient advocates consider quality of life to be just as important, if not more important sometimes than overall survival numbers. Because patient advocates will say, "Well if I live longer but I'm miserable living longer, yes that works for regulatory agencies but doesn't work for us." So PROs clearly are very, very important. And, in fact, we just literally had a meeting in Houston, the IBCG meeting where PROs were a main point of what we discussed. So incorporating PROs in everything we do, not just this but everything we do, Dr. Necchi, myself, everybody involved in these fields realizes it is very, very important. So absolutely. Dr. Davide Soldato: I want to thank again Professor Necchi and Professor Kamat for joining us today. Dr. Andrea Necchi: Thank you. Dr. Ashish Kamat: It is our pleasure. Dr. Davide Soldato: Thanks again and we appreciate you sharing more on your JCO article titled "Endpoints for the Next Generation Bladder-Sparing Perioperative Trials for Patients with Muscle-Invasive Bladder Cancer." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcast. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Il Genoa ha inaugurato il nuovo Store di Piazza Banchi, un altro piccolo tassello che ricongiunge il club col cuore della città che rappresenta. Ripercorriamo le ultime ore, scandite anche dalle parole di Sucu tra la festa del settore giovanile e l'inaugurazione del medesimo store. Buoncalcioatutti!

Maracanà con Marco Piccari e Lucio Marinucci. Ospite: Brambati:"La Juve è senza leader. La proprietà ha fatto dei disastri. Ho visto un Napoli scarico mentalmente contro il Benfica. Farei di tutto per rinnovare Maignan più che Pulisic. De Rossi spero faccia un bel percorso con il Genoa"

Join Jake and Matt as they run you through Matchday 14 of the 25/26 Serie A Season on their special 200th episode. We wish to thank everyone who's joined us on this journey and hope you'll continue listening to us banter about calcio!Timestamps0:00 Intro and Rundown 21:59 Napoli 2-1 Juve 43:06 Inter 4-0 Como 58:17 Torino 2-3 Milan 1:15:34 Cagliari 1-0 Roma 1:29:45 Sassuolo 3-1 Fiorentina 1:45:41 Lazio 1-1 Bologna 1:58:23 Hellas 3-1 Atalanta 2:05:58 Cremonese 2-0 Lecce 2:14:50 Pisa 0-1 Parma 2:22:38 Udinese 1-2 Genoa 2:28:56 Quickfire Predictions 2:32:07 Wisdom with the Wank 2:36:07 The Pride of Indonesia 2:38:25 Outro Become a patreon: ⁦https://patreon.com/Serieaspotlight?⁩utm_medium=unknown&utm_source=join_link&utm_campaign=creators hare_creator&utm_content=copyLinkSpecial Shoutout to our Media Partners Benevo Bid - Check out their collection here; ⁦https://benevobid.com/⁩#acmilan #inter #juventus #torino #napoli #atalanta #bologna #fiorentina #roma #lazio #lecce #cagliari #udinese #monza #venezia #como #hellasverona #parma #empoli #genoa #football #soccer #footballpodcast #podcast PatreonYoutube: ⁦https://www.youtube.com/@serieaspotlight⁩Instagram: ⁦https://www.instagram.com/serieaspotlight/⁩Twitter: ⁦https://x.com/SerieASpotlight?⁩

Il Genoa vince a Udine, dopo 680 giorni torna a vincere due gare di fila in Serie A e si porta a +4 sulla zona retrocessione in attesa di ospitare al Ferraris l'Inter. Il nostro commento in questa puntata. Buoncalcioatutti!

Il lungo spezzatino di campionato valido per la 14esima giornata di Serie A, si è concluso con ben tre posticipi nel lunedi di festa per l'Immacolata Concezione. Tre partite: tre vittorie in trasferta.

Audra vs. Claire smackdown!; Victor unleashes the AI… on Matt Clark!; Noah and Sienna escape; Jack takes Jabot offline; Cane chooses Phyllis; and Victoria and Nate grow closer. Visit https://www.yrchat.com to chat with fun and friendly fans of The Young and the Restless. THIS WEEK: Ali’s Y&R Recap, The Weekly Y&R Polls, a “Who Said […]

Mister De Rossi parte con 28 giocatori per la trasferta di Udine, che segnerà l'ultima gara non di cartello prima del trittio Inter, Atalanta e Roma. Le ultime in vista di Udinese-Genoa e il focus, nel finale di puntata, sugli ultimi risultati di Genoa Women, Primavera e giovanili. Buoncalcioatutti!

Steve Wyss, James Eastham and Dan Roebuck look at the best bets for this weekend's matchups in LaLiga, Bundesliga, Serie A and Ligue 1. Intro - 00:00 Fade Midweek LaLiga teams? - 02:20 Napoli v Juventus - 08:47 Toulouse v Strasbourg - 13:55 Nice v Angers - 17:29 Valencia v Sevilla - 25:08 Cagliari v Roma - 27:50 Bundesliga Parlay - 30:40 Udinese v Genoa - 35:08 Serie A Title talk - 38:02 Osasuna v Levante - 42:00

Il punto in casa Genoa, tra la partita contro l'Udinese e la visita di ieri della squadra all'ospedale Gaslini. Domani parla De Rossi. Buoncalcioatutti!

Seconda serata di Coppa Italia con le big che passano il turno come da pronostico: l'Atalanta travolge il Genoa e ai quarti troverà la Juve, l'Inter passeggia sul Venezia e il Napoli porta a casa la qualificazione dopo una lunga serie di rigori ai quali partecipa come protagonista anche Milinkovic Savic nel doppio ruolo di portiere e rigorista. Commentiamo tutto con Franco Ordine del Giornale e Massimo Paganin dalla postazione di telecronaca di Sport Mediaset. Oggi una puntata di Endurance Race che guarda, inevitabilmente, all'ultimo atto della F1: ad Abu Dhabi si deciderà chi tra Piastri, Norris e Vertappen sarà campione del mondo. Ne parliamo con Gionata Ferroni e Umberto Zapelloni.

Fluent Fiction - Italian: A Christmas Mix-Up: Sweet Surprises in a Roman Hospital Find the full episode transcript, vocabulary words, and more:fluentfiction.com/it/episode/2025-12-04-23-34-02-it Story Transcript:It: Giovanni entrò di corsa nell'ospedale affollato di Roma.En: Giovanni rushed into the crowded hospital in Rome.It: Era il giorno prima di Natale e l'aria era piena di eccitazione e cori di auguri.En: It was the day before Christmas and the air was filled with excitement and the sound of well-wishers' songs.It: Le decorazioni natalizie brillavano sulle pareti: festoni di vischio e lucine colorate illuminavano i corridoi.En: Christmas decorations sparkled on the walls: garlands of mistletoe and colorful lights illuminated the corridors.It: Giovanni stringeva una scatola avvolta in carta rossa, contenente il suo prezioso Panettone fatto in casa.En: Giovanni was holding a box wrapped in red paper, containing his precious homemade Panettone.It: Era stato un suo segreto per settimane, un desiderio ardente di dimostrare le sue abilità culinarie al personale.En: It had been his secret for weeks, a burning desire to showcase his culinary skills to the staff.It: Nel caos della sala d'attesa, Giovanni si distrasse mentre salutava un amico.En: In the chaos of the waiting room, Giovanni got distracted while greeting a friend.It: Senza rendersene conto, posò la sua scatola accanto a un'altra identica.En: Without realizing, he placed his box next to another identical one.It: Con un sorriso sulle labbra, prese la scatola sbagliata e si diresse verso il reparto dove lavorava il suo amico Luca, pronto a condividere il suo dolce con i colleghi.En: With a smile on his face, he picked up the wrong box and headed toward the department where his friend Luca worked, ready to share his sweet creation with his colleagues.It: Nel frattempo, Marco, un paziente del reparto ortopedico, osservava nervoso la scatola rimasta.En: Meanwhile, Marco, a patient in the orthopedic department, nervously watched the box that remained.It: Era assolutamente orgoglioso del suo frutto di lavoro, un Pandolce genovese che aveva preparato in convalescenza.En: He was absolutely proud of his fruit of labor, a Pandolce from Genoa he had prepared during his recovery.It: Quando scoprirono di aver preso le scatole sbagliate, Giovanni e Marco erano già uno davanti all'altro nella piccola caffetteria dell'ospedale.En: When they discovered they had taken the wrong boxes, Giovanni and Marco were already facing each other in the small hospital cafeteria.It: "Luca, ho preso una scatola sbagliata!"En: "Luca, I took the wrong box!"It: esclamò Giovanni.En: exclaimed Giovanni.It: "Devo ritrovarla."En: "I need to find it."It: Marco, fermo e deciso, rispose: "Questo è il mio Pandolce.En: Marco, still and determined, replied, "This is my Pandolce.It: È fatto con amore e ricordi della mia terra."En: It's made with love and memories of my homeland."It: Giovanni studiò il dolce di Marco sospettoso.En: Giovanni studied Marco's sweet suspiciously.It: Convinto dello scambio, decise di assaggiare un pezzetto del Pandolce per confermare i suoi sospetti.En: Convinced of the switch, he decided to taste a piece of the Pandolce to confirm his suspicions.It: Il sapore degli alchechengi e delle mandorle lo colpì subito.En: The taste of dried gooseberries and almonds hit him immediately.It: "Questo ha delle mandorle!"En: "This has almonds!"It: esclamò Giovanni.En: exclaimed Giovanni.It: "Il mio Panettone ha avuto una crema d'arancia!"En: "My Panettone had an orange cream!"It: Marco esitò, guardando il pezzo di Pandolce che Giovanni aveva mordicchiato.En: Marco hesitated, looking at the piece of Pandolce that Giovanni had nibbled.It: Scoppiò una risata quando si rese conto della situazione assurda.En: He burst into laughter when he realized the absurd situation.It: "E così tu hai il mio Pandolce!"En: "So you have my Pandolce!"It: Giovanni rise, sollevato e divertito.En: Giovanni laughed, relieved and amused.It: "Sì, e tu hai il mio Panettone!"En: "Yes, and you have my Panettone!"It: Le risate rimbombarono nella caffetteria mentre i due uomini finalmente si scambiavano i dolci.En: Laughter echoed in the cafeteria as the two men finally exchanged the sweets.It: Intorno a loro si diffusero sorrisi.En: Smiles spread around them.It: Giovanni prese un respiro profondo e fece un discorso sentito sulla bellezza delle tradizioni e sull'importanza di condividerle.En: Giovanni took a deep breath and gave a heartfelt speech about the beauty of traditions and the importance of sharing them.It: "Il Natale non è essere perfetti, ma stare insieme," disse.En: "Christmas is not about being perfect but being together," he said.It: Con i cuori più leggeri, decisero di condividere entrambi i dolci con tutti nella caffetteria.En: With lighter hearts, they decided to share both sweets with everyone in the cafeteria.It: Le fette furono distribuite, e ben presto, l'intera stanza era riempita da suoni di complimenti e gioia.En: The slices were distributed, and soon, the entire room was filled with sounds of compliments and joy.It: Alla fine della giornata, Giovanni si sentì rinnovato.En: By the end of the day, Giovanni felt renewed.It: Aveva capito che la sua passione per la cucina era apprezzata e che il Natale era davvero speciale quando era condiviso.En: He realized that his passion for cooking was appreciated and that Christmas was truly special when shared.It: Seduti vicini, Giovanni, Marco e Luca brindavano alle nuove amicizie e alle risate, felici di aver trasformato una piccola confusione in un grande momento di allegria natalizia.En: Sitting together, Giovanni, Marco, and Luca toasted to new friendships and laughter, happy to have turned a small mix-up into a big moment of Christmas cheer. Vocabulary Words:crowded: affollatoexcitement: eccitazionewell-wishers: cori di augurigarlands: festonihomemade: fatto in casato showcase: dimostrareculinary: culinariechaos: caosdistracted: distrasseidenti-cal: identicato head: diresseorthopedic: ortopediconervously: nervosoproud: orgogliosorecovery: convalescenzadetermined: decisoto study: studiòsuspiciously: sospettososwitch: scambiodried gooseberries: alchechengito hit: colpìorange cream: crema d'aranciato hesitate: esitòto burst into laughter: scoppiò una risatarelieved: sollevatoamused: divertitoto echo: rimbombaronoheartfelt: sentitoto distribute: distribuiteto toast: brindavano

Scarica Revolut gratis con il mio link per ricevere un bonus di benvenuto di €20*: https://get.revolut.com/e9Jc/podcast1*Si applicano condizioni minimeNessun problema per Inter e Atalanta che superano agevolmente Venezia e Genoa, deve combattere fino ai rigori (ben ad oltranza) il Napoli di Antonio Conte che comunque riesce a passare il turno. Il mercoledì di Coppa Italia raccontato a Potrero da Simone Indovino e Luca Tumminello. Potrero, dove tutto ha inizio. Un podcast sul calcio italiano e internazionale.Su Como TV (https://tv.comofootball.com) nel 2025 potete seguire in diretta e gratuitamente le partite della Saudi Pro League, Saudi King's Cup, Supercoppa d'Arabia, Copa Libertadores, Copa Sudamericana, Recopa, Liga Profesional Argentina, Trofeo de Campeones argentino, Eredivisie, Coppa di Francia, Scottish Premiership, Coppa di Scozia, Scottish League Cup, Scottish Championship, Coppa di Portogallo, Supercoppa di Portogallo, HNL croata e tutti i contenuti di calcio italiano e internazionale on demand.Diventa un supporter di questo podcast: https://www.spreaker.com/podcast/potrero--5761582/support.

Scarica Revolut gratis con il mio link per ricevere un bonus di benvenuto di €20*: https://get.revolut.com/e9Jc/podcast1*Si applicano condizioni minimeLa Coppa Italia entra nel vivo, partono gli ottavi: la Juve vince 2-0 contro l'Udinese, grazie all'autogol di Palma e alla rete di Locatelli. Oggi si giocano Atalanta-Genoa, Napoli-Cagliari e Inter-Venezia. Il commento ai bianconeri e la presentazione delle gare odierne con Angelo Taglieri e il nostro inviato allo Stadium Tommaso Murdocca.Potrero, dove tutto ha inizio. Un podcast sul calcio italiano e internazionale.Su Como TV (https://tv.comofootball.com) nel 2025 potete seguire in diretta e gratuitamente le partite della Saudi Pro League, Saudi King's Cup, Supercoppa d'Arabia, Copa Libertadores, Copa Sudamericana, Recopa, Liga Profesional Argentina, Trofeo de Campeones argentino, Eredivisie, Coppa di Francia, Scottish Premiership, Coppa di Scozia, Scottish League Cup, Scottish Championship, Coppa di Portogallo, Supercoppa di Portogallo, HNL croata e tutti i contenuti di calcio italiano e internazionale on demand.Diventa un supporter di questo podcast: https://www.spreaker.com/podcast/potrero--5761582/support.

Il Genoa sta in partita 17', poi scricchiola dopo la rete del vantaggio dell'Atalanta e crolla del tutto quando rimane in dieci al 35' di gioco. Una bruttissima partita dei rossoblù, che si presentano sì rimaneggiati alla sfida contro la formazione di Palladino, ma non danno mai accenni di scossa dopo lo svantaggio. Il nostro commento alla gara

Locatelli fa le cose per bene e trascina la Juventus ai quarti di Coppa Italia. Battuta l'Udinese 2-0 senza troppi patemi e grazie agli errori di Palma che per anticipare David, su un cross di McKennie, batte in scivolata il proprio portiere Sava e decreta il primo vantaggio bianconero.

Join Jake and Matt as they run you through the 13th Matchweek of the Serie A, with a tight race at the top of the league, there's lots to talk about...Timestamps0:00 Intro & Rundown21:10 Milan 1–0 Lazio44:59 Roma 0–1 Napoli57:26 Pisa 0–2 Inter1:05:39 Atalanta 2–0 Fiorentina1:19:31 Juve 2–1 Cagliari1:33:02 Bologna 1–3 Cremonese1:41:04 Como 2–0 Sassuolo1:47:39 Lecce 2–1 Torino1:58:31 Genoa 2–1 Hellas Verona2:11:16 Parma 0–2 Udinese2:12:09 Predictions2:15:22 Wisdom With the Wank2:16:10 The Pride of Indonesia2:17:00 OutroBecome a patreon: ⁦https://patreon.com/Serieaspotlight?⁩utm_medium=unknown&utm_source=join_link&utm_campaign=creators hare_creator&utm_content=copyLinkSpecial Shoutout to our Media Partners Benevo Bid - Check out their collection here; ⁦https://benevobid.com/⁩#acmilan #inter #juventus #torino #napoli #atalanta #bologna #fiorentina #roma #lazio #lecce #cagliari #udinese #monza #venezia #como #hellasverona #parma #empoli #genoa #football #soccer #footballpodcast #podcast PatreonYoutube: ⁦https://www.youtube.com/@serieaspotlight⁩Instagram: ⁦https://www.instagram.com/serieaspotlight/⁩Twitter: ⁦https://x.com/SerieASpotlight?⁩

Nick and Sharon search for Noah; Thanksgiving with the Newmans and Abbotts; Ultimatum for Cane; and Danny and Christine’s wedding reception! Visit https://www.yrchat.com to chat with fun and friendly fans of The Young and the Restless. THIS WEEK: Ali’s Y&R Recap, The Weekly Y&R Polls, a “Who Said It” Quote Game, and Opening “The Chatterbox” […]

After PSV's decisive victory over Liverpool, we have to ask: did Arne Slot really just get taught a lesson from Peter Bosz? And what does such a commanding win mean for PSV's European ambitions this season?Dotun and Andy are joined by Lars to break it all down. Also on the show, what will Daniele De Rossi have to do to restore Genoa's stature? Would a strong season at a club like Strasbourg be enough to get Ben Chilwell back into England contention? What will Joan Garcia's return mean for Barcelona?Ask us a question on Twitter, Instagram and TikTok, and email us here: otc@footballramble.com.For ad-free shows, head over to our Patreon and subscribe: patreon.com/footballramble.***Please take the time to rate and review us on Apple Podcasts or wherever you get your pods. It means a great deal to the show and will make it easier for other potential listeners to find us. Thanks!*** Hosted on Acast. See acast.com/privacy for more information.

Nuestro invitado en el episodio #331 de Máximo Desempeño es Nicolás Maya, presidente del Club Deportivo Equidad y ejecutivo del fútbol con visión global que ha operado en tres continentes. Después de nueve años construyendo una carrera exitosa en McKinsey & Company, Nicolás tuvo el coraje de renunciar a la seguridad para perseguir su verdadera pasión: transformar el fútbol desde adentro. Pero el camino no fue lineal. Intentó emprender, invirtió su dinero y tiempo, y fracasó. Ese tropiezo le enseñó una lección invaluable: pedir ayuda no es rendirse, es la única forma de no rendirse. Con su sueño intacto y más sabio que antes, lideró la adquisición de seis clubes en Estados Unidos, participó en juntas directivas del Genoa de Italia y Vasco da Gama de Brasil, y hoy lidera un proyecto ambicioso que busca revolucionar el fútbol colombiano con una visión moderna, sostenible y profundamente conectada con la comunidad. Vive bajo un lema inquebrantable: "La actitud y el compromiso, no se negocian". Además, Pablo profundiza en "El Secreto de la Confianza: Haz Lo Que Más Temes", una reflexión transformadora sobre cómo se construye la confianza real. Descubre por qué nunca estarás listo para lo que tienes que hacer y el miedo no proviene de tu incapacidad sino de tu inexperiencia, cómo cada vez que evitas lo que temes le envías a tu cerebro el mensaje "no soy capaz" y tu mente responde bajando tu confianza, y por qué la neurociencia confirma que cada vez que sobrevives a algo que temías, tu cerebro actualiza su modelo de lo que eres capaz de hacer. Aprende la diferencia crucial entre confianza falsa y confianza real: una viene de elogios externos y se desmorona a la primera crítica, la otra viene de evidencia interna y es inquebrantable porque la construiste tú. Descubre por qué la confianza no es ausencia de miedo sino acción a pesar del miedo, y cómo el movimiento genera claridad mientras que la preparación infinita solo genera parálisis. Un episodio que te desafiará a preguntarte: ¿Qué has estado evitando porque esperas sentirte listo? ¿Qué conversación difícil, qué proyecto que te emociona pero te aterra, qué oportunidad estás posponiendo? ¿Cuánto te está costando mantener tu zona de confort? Tu confianza está esperándote exactamente donde está tu miedo.

Danny and Christine’s wedding!; Phyllis and Cane hook up; Claire plans revenge on Audra; and Noah/Sienna are kidnapped. Visit https://www.yrchat.com to chat with fun and friendly fans of The Young and the Restless. THIS WEEK: Ali’s Y&R Recap, The Weekly Y&R Polls, a “Who Said It” Quote Game, and Opening “The Chatterbox” to Read Fan […]

https://thecommunists.org/2025/09/24/news/genoa-dockers-convene-european-conference-non-cooperation-genocide/ This weekend, port worker delegations will meet with workers involved in the direct and/or indirect supply chain of transporting or producing war materials. Dockworkers in the Italian port of Genoa have consistently led the way in obstructing the efforts of the Nato war machine. As well as stopping arms shipments to Israel they have also stopped shipments of munitions to Ukraine and to Saudi Arabia (for use in its genocidal war against Yemen). Their example is one that should be followed by workers everywhere. Subscribe! Donate! Join us in building a bright future for humanity! www.thecommunists.org www.lalkar.org www.redyouth.org Telegram: t.me/thecommunists Twitter: twitter.com/cpgbml Soundcloud: @proletarianradio Rumble: rumble.com/c/theCommunists Odysee: odysee.com/@proletariantv:2 Facebook: www.facebook.com/cpgbml Online Shop: https://shop.thecommunists.org/ Education Program: Each one teach one! www.londonworker.org/education-programme/ Join the struggle www.thecommunists.org/join/ Donate: www.thecommunists.org/donate/

Guest Dr. Rusha Bhandari and host Dr. Davide Soldato discuss JCO article "Health Outcomes Beyond Age 50 Years in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study, " with a particular focus on mortality data, development of secondary malignancies and the importance of education for both patients and healthcare providers regarding long-term follow-up and care. TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Dr. Davide Soldato: Hello, and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, Medical Oncologist at Ospedale Policlinico San Martino in Genoa, Italy. Today, we are joined by JCO author, Dr. Rusha Bhandari, a Pediatric Hematologist-Oncologist and Assistant Professor in the Department of Pediatrics and Population Science at City of Hope, California. Today, we will be discussing the article titled "Health Outcomes Beyond Age 50 Years in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study." So, thank you for speaking with us, Dr. Bhandari. Dr. Rusha Bhandari: Thanks so much for having me. Dr. Davide Soldato: So, I just want to go straight ahead in the paper and start from the title. So, we heard that you included in this study childhood survivors of pediatric cancer that were aged 50 years or higher. So, this is a very critical life stage when we know that there are a lot of aging-related comorbidities that can happen, also in the general population but potentially specifically in childhood cancer survivors. So, first of all, I wanted to ask you, why this specific study in this very specific population? Because I think that we had already some data in younger survivors, but now we are focusing specifically on patients aged 50 or more. Dr. Rusha Bhandari: Absolutely. So, to answer that question, I'll take a little bit of a step back in terms of where we are now and where we came from in terms of treatment for childhood cancers. So, thankfully, we now have great curative therapies and survival rates for many childhood cancers, including the most common ones. But this was not necessarily the case 50 or more years ago. So, we essentially are now seeing the first generation of older survivors who are 30, 40, or more years from completion of their cancer treatment. As you pointed out, we know from younger survivors that they have a markedly higher risk of malignancies and health conditions than the general population. You don't typically expect to see things like heart disease or diabetes, for example, in a young adult. But the question that remained was what the health status and risk of these conditions are in survivors who are entering this critical age, as you mentioned, 50 or older, when you do start to see these aging-related changes in the general population. And the question is whether we're still observing increased risks related to cancer treatment that was delivered 30 or more years ago in these survivors who are now entering ages 50 and beyond. Dr. Davide Soldato: Thanks so much. You used the data from a study that is called the Childhood Cancer Survivor Study. So, just a little bit of explanation for our listeners. How is the study conducted? What type of data are you collecting? And specifically for the interest of the study that was reported in this manuscript, which outcomes were really important for you and were so evaluated in the manuscript? Dr. Rusha Bhandari: Yes. So, the Childhood Cancer Survivor Study is a really excellent resource that combines information from children who were treated across North America at various different centers and sites. So it gives us a really good understanding of how different survivors are doing as they do progress through their survivorship journey. The Childhood Cancer Survivor Study includes a baseline questionnaire when participants are first eligible or first enter the study, and then includes a series of follow-up questionnaires to really understand how they're doing, like I mentioned, as they progress throughout their survivorship journey. And so for this study, we really wanted to take a global look at how these patients were doing as they entered that older age range. And so we wanted to look at outcomes ranging from mortality through the health conditions that we've seen from other survivorship studies, including subsequent malignant neoplasms, other health conditions, I mentioned earlier heart disease and other comorbidities we know survivors can be at increased risk for, and also things like frailty, which we know is, you know, the most widely recognized phenotype of aging. And we see that earlier on in our younger survivors. We want to see how this translated to these older survivors and then also other health outcomes like their health status. What is their self-report of their physical health, their mental health? Things like that. So we wanted a very comprehensive understanding of their health. Dr. Davide Soldato: This is a very comprehensive study. Right now it includes more than 30,000 patients that have been treated for childhood cancer, but specifically looking at the question of survivors aged 50 years or higher, you included more than 7,000 patients inside of this study. So, looking at the first outcome that you mentioned, which I think it's also one of the most important, you look specifically at mortality, and in this specific population, you saw a striking three-fold increase in mortality when comparing these survivors with the general population. I just wanted to dive in this result and ask you: What do you see as the main driver for this excess mortality in this population of survivors? And as you were mentioning, the study also collects information about the treatment received. So, was there any association with a specific kind of treatment that was received for curing these childhood cancers? Dr. Rusha Bhandari: I agree. I would say it's striking to see that mortality risk among the survivors relative to the general population. And we do know, again from prior studies, that survivors of childhood cancer do have an increased risk of mortality compared to the general population, but I think looking at those curves of the cumulative mortality risk was really quite striking as they diverge, and that's, you know, just so long past their initial diagnosis and treatment. We know that subsequent malignant neoplasms or secondary cancers are a really an important contributor to mortality among survivors. And I think it was important to note that even in these older survivors, it's still such an important contributor to mortality, and I think this really highlights the need for us to better understand what is driving specific secondary cancers and what are the differences in the biology and treatment approaches for some of these cancers? And how might that then be contributing to the mortality risk? Dr. Davide Soldato: Related to the treatment mortalities - because I think that one of the main forces of the study, as it is conducted, is that it contains a lot of information regarding radiotherapy, allogeneic transplant, surgery, type of chemotherapy received by these survivors - so, are we able right now with the data that we have to pinpoint which of these treatments can potentially lead to such increased risk of mortality? Dr. Rusha Bhandari: So, we weren't able to look at the comprehensive treatment exposures and mortality risk for this paper. So that might be one of the questions I would put on the side. We were able to look at that in relation to subsequent malignant neoplasms and health conditions though, as you mentioned. Dr. Davide Soldato: Another thing that I think is very important is that you were able to look at specific causes for mortality. So for example, you mentioned the increased rate of neoplasm in this population and specifically, more or less 7.6% of the patients that were included in the study developed another neoplasm after the ones they were cured for in the childhood period. So, you saw a wide range of cancer, for example, bone and soft tissue sarcomas, breast cancer, genitourinary cancer. And as you were mentioning, there were some associations for treatment modalities that were associated with a higher risk of developing this type of cancer. Can you expand a little bit on this? Dr. Rusha Bhandari: Absolutely. And so the key part here was that we really looked at any of these outcomes that occurred beyond age 50. What we found was there is still an increased risk of secondary cancers beyond that initial childhood cancer diagnosis, but when we really looked at that data, it was specifically among survivors who had a history of receiving radiation. And we did not necessarily see an association between different chemotherapy exposures and secondary cancers. And I think this speaks to what we're now learning in terms of the very long-term effects of radiation and how that impacts ongoing health risk even in patients who are 30 or more years out from their treatment. And I think it really highlights the importance of these- the efforts that have been made in the more recent decades to really try and reduce or eliminate radiation where possible, you know, as we've come to understand more about these long-term effects from it. Dr. Davide Soldato: A clear association with radiation therapy but no association when we look at specific types of chemotherapy that were used for curing this childhood cancer. Another thing that I think it's very interesting and you briefly mentioned before is that potentially when we look at these secondary malignant neoplasm that develop in this situation, we might also see some outcomes that are not comparable to the one of the general population, meaning that we managed to cure less this type of cancer when they develop in these childhood survivors. So, I just wanted to understand if you could provide us with a little bit of perspective also from a clinical standpoint being a pediatric hematologist-oncologist as to why this might be happening and how can we potentially increase the cure rate also in this population of childhood cancer survivors? Dr. Rusha Bhandari: Absolutely. While that was not the focus of this study, it was something that we were certainly interested in is understanding how even once a childhood cancer survivor, for example, develops a health condition or a secondary cancer further into survivorship, how does that outcome then differ from someone in the general population? And there's a lot of interest in ongoing studies actually evaluating that and understanding what are the differences from the initial presentation, biology, the characteristics of that cancer, through how they're treated. So I don't know if we have all of the answers for that quite yet, but you can imagine if someone hypothetically had a history of receiving a lot of anthracycline chemotherapy or already having received a lot of radiation, that might impact what treatment they might receive for that secondary cancer or if they already have other existing comorbidities that need to be taken into consideration. Dr. Davide Soldato: Speaking about comorbidities, you were mentioning in the beginning that one of the focuses of this scientific work was really to try and see whether also this type of adverse health outcomes that can be potentially related to treatments were more frequent among these childhood cancer survivors. So I think that it's very interesting that for this comparison, you were able to use the data from the siblings of the patients who were included inside of the study. So, just a little bit of a comment on why you decided to use this specific methodology, which I think has a very nice touch to it when we look at these outcomes like, for example, diabetes or cardiovascular disease, and in general, do we see an increased number of chronic health conditions among survivors who were treated for childhood cancers? Dr. Rusha Bhandari: Yes, so this is a really excellent strength of the Childhood Cancer Survivor Study is that they have information, longitudinal information, on survivors as well as their siblings. So, you know, when we were discussing the design of the study, I mentioned that we have initial baseline questionnaires as well as multiple follow-up questionnaires, and that is for both the survivors and the siblings. And so we're able to really understand their health course over time. We chose to evaluate sibling data because then you're really able to look at people who have similar characteristics, right? Similar environmental exposures in theory, potentially similar genetic predispositions and makeups and things like that. And so you can really try and have as good of a comparison as possible. Dr. Davide Soldato: Did we see any increase in chronic health condition when looking at survivors compared to the siblings? Dr. Rusha Bhandari: We did. And while that's been reported before, again, I think it's important to demonstrate that in this older population when you would expect that these siblings would now also be starting to develop different health conditions. Dr. Davide Soldato: One thing that was very interesting is that when we look at the coexistence of multiple comorbid conditions and chronic condition in this population, we also see that for some of these survivors, they basically have the same rates of comorbidities as compared to siblings who are potentially 20 years older than them. So I think that there is really that striking point, as you were mentioning before, of accumulation of changes, also physiological changes that can potentially drive a higher frailty index, which was also higher when looking at these survivors compared to their siblings. One outcome that was really not that worse when we look at survivors of childhood cancer was actually mental health. And as I read the paper, it was something that really surprised me a little bit because you would imagine that going through such a harsh diagnosis, such very complex treatment, very early in their life could potentially lead to some worse health outcomes also in terms of mental health over time. But this was not seen. And just a comment on this, because I think it's a very surprising data. Dr. Rusha Bhandari: Yes, I appreciate that question. So, as you mentioned, mental health is such an important issue for patients, both those undergoing treatment as well as those in long-term survivorship. And in our study, we found that survivors were not more likely, as you mentioned, to report poor mental health compared to their siblings. And I think there's a few possible reasons for this. You know, again, this is self-reported data amongst siblings and survivors who survived to at least 50 years of age and completed a questionnaire. And so that is the group of individuals that we were able to evaluate this in, so we have to keep that in mind. But I think our findings may also reflect the resilience of this particular cohort of aging survivors that we included. This finding has been reported in other studies of survivors as well, and so I think it very well may speak to the resilience of the cohort that we're looking at. Dr. Davide Soldato: Going back just a little bit, you mentioned that the majority potentially of these survivors who were included in the current analysis were treated between 1970s and 1980s. So, as you were mentioning before, radiotherapy was seen as a significant contributor to second neoplasm and also to the increase of this chronic health condition. So, do you believe that there is still a role for these survivorship studies as we are approaching treatment modalities where radiotherapy is administered less frequently or with lower doses or omitted at all in the treatment course of these survivors? Dr. Rusha Bhandari: Absolutely. I think you mentioned a very important point, which is these findings are most applicable to the patients who were included in this cohort or similar cohorts, those who were treated in the 1970s and 80s who now are 50 years or older at this point in time. And as you know, treatment modalities have really changed. You know, as you mentioned, we'll use less radiation in many cases whenever possible, but there are so many new modalities, so many different chemotherapeutic agents, immunotherapy. There's so much more we need to learn about the long-term effects of some of these newer treatment modalities. And also, we've been able to really intensify our treatment regimens with improvements in both treatment approaches and supportive care. And so I think we have a lot to learn about those late effects, and ongoing studies are certainly needed as we continue to have this growing population of older survivors. Dr. Davide Soldato: And now a more general question which builds on the results of the study but goes a little bit beyond what was the scope of the research. So we have just discussed that there is an excess mortality in general, there is a higher risk for secondary malignancies in this population, we see higher accumulation of chronic comorbid conditions that need to be treated. So building on these results, in your opinion, what would be the best framework to follow up these patients over time? Because I imagine that for some of these patients who have been treated 30, 40 years before the moment where we see this type of events, they can be potentially also discharged from more specialistic medical care. So what is the best course of action? Should we keep all of these patients under observation in a very specialistic environment under the care of the oncologist or the pediatric oncologist? Should we create a stronger bond with general practitioners so they know that there is this problem? Dr. Rusha Bhandari: Yes, I mean, I think you're reading my mind. We thankfully do have evidence-based guidelines. We utilize the Children's Oncology Group Long-Term Follow-Up Guidelines, which include screening recommendations for secondary cancers, chronic health conditions, everything based on the underlying diagnosis and treatment that these patients received. But we recognize that a large proportion of these survivors do not continue to have lifelong follow-up at a survivorship center, but really do need that specialized screening based on their treatment that they received. And I think for that reason, it's so important that we continue to build relationships with their primary care providers and really make sure that both patients and their providers have this information at hand regarding what their treatment is and what the screening is that they need and that we be able to have this community whereby we are able to help inform the screening in our own survivorship clinics, but also help guide some of the primary care providers who are going to be seeing these patients in the long run. Dr. Davide Soldato: Do we have any data showing what is the adherence rate of these patients to this type of continuous screening and monitoring over time? Because I imagine that that might also be a point for improvement in terms of quality of care. Can we retain as much childhood cancer survivors as we want as we are learning that there are all these potential negative health outcomes over time? Dr. Rusha Bhandari: We definitely within the survivorship community do want to help make sure as many survivors as possible are being engaged, again, whether it's at their specific cancer center or whether it's in the community, recognizing that for many reasons, it's not feasible to always return to that cancer center for your regular survivorship care. I think there's a lot we can do. Going a little bit outside the scope of your question, but I think there's a lot that we can do nowadays in terms of telehealth and being able to communicate with patients and their providers even if they're geographically not located right near us. But we do have data that shows that the further out many patients get from their initial diagnosis and treatment, the less often they might follow up with a survivorship provider. Some of this varies by different treatment. Dr. Davide Soldato: So, basically the final question is that we need more education and potentially more resources for survivorship clinics and in general to better inform patients and providers about these potential long-term outcomes. Dr. Rusha Bhandari: That's certainly a focus of our survivorship program, for example, is to make sure that we're able to educate patients, inform them of their risks, and why certain screening tests are recommended at certain times in their survivorship journey. And then I think again, thankfully nowadays with all of the electronic medical records and different methods for us to communicate, there's a lot of opportunity for us to continue building these relationships with those primary care providers and making sure they have the information at their fingertips as well as to be able to work in conjunction with these patients to continue to formulate their plans and carry out these screenings and then again, like I was saying, have an easy open line of communication with the oncology centers if they do have any questions. Dr. Davide Soldato: Thanks so much. This brings us to the end of this episode. I would like to thank again Dr. Bhandari for joining us today. Dr. Rusha Bhandari: Thank you so much. It's been a real pleasure speaking with you. Dr. Davide Soldato: And we appreciate you sharing more on your JCO article titled "Health Outcomes Beyond Age 50 Years in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Join Matt and Jake as they run you through the latest Serie A Matchday before the International Break broke out, and listen to their thoughts on the latest managerial appointments in the Serie A!Timestamps00:00 Intro and Updates 2:31 Matchday 11 1:19:00 Vanoli's Fiorentina 1:24:53 Palladino's Atalanta 1:47:06 Wisdom With the Wank 1:54:08 Pride of Indonesia 1:58:11 De Rossi's Genoa 1:57:15 OutroBecome a patreon: ⁦https://patreon.com/Serieaspotlight?⁩utm_medium=unknown&utm_source=join_link&utm_campaign=creators hare_creator&utm_content=copyLinkSpecial Shoutout to our Media Partners Benevo Bid - Check out their collection here; ⁦https://benevobid.com/⁩#acmilan #inter #juventus #torino #napoli #atalanta #bologna #fiorentina #roma #lazio #lecce #cagliari #udinese #monza #venezia #como #hellasverona #parma #empoli #genoa #football #soccer #footballpodcast #podcast PatreonYoutube: ⁦https://www.youtube.com/@serieaspotlight⁩Instagram: ⁦https://www.instagram.com/serieaspotlight/⁩Twitter: ⁦https://x.com/SerieASpotlight?⁩

When Sydney Sweeney said "Jeans are not Controversial" Mrs. P had to investigate and what she found was astounding. From Sydney Sweeneys stalling career, to her plans with Geoff Bezos,  to the origins of Jeans in India, Britain, America. And how they were touched by the republic of Genoa, the British Ra, East India Trading Company, Mahatma Gandhi, and the prison industrial complex. And then of course back to Sydney Sweeneys GQ interview. GET THE MISCELLANEOUS IMMORALITY SHIRT HERE:

Phyllis seduces Cane; Noah and Sienna’s affair; Adam plans to humiliate Billy; Mariah shuts Tessa out; and The return of Pietro! Visit https://www.yrchat.com to chat with fun and friendly fans of The Young and the Restless. THIS WEEK: Ali’s Y&R Recap, The Weekly Y&R Polls, a “Who Said It” Quote Game, and Opening “The Chatterbox” […]

On November 12th, McHenry Police received a call that a truck hit a curb and a sign. SHAW LOCAL reports officers found 58-year-old James R. Conaway of Genoa asleep behind the wheel of the truck. According to information filed in McHenry County court, Conaway was charged with aggravated DUI, and a judge cited Conaway's history of alcoholism, when he denied Conaway's pretrial release from county jail.

On November 12th, McHenry Police received a call that a truck hit a curb and a sign. SHAW LOCAL reports officers found 58-year-old James R. Conaway of Genoa asleep behind the wheel of the truck. According to information filed in McHenry County court, Conaway was charged with aggravated DUI, and a judge cited Conaway's history of alcoholism when he denied Conaway's pretrial release from county jail.

On November 12th, McHenry Police received a call that a truck hit a curb and a sign. SHAW LOCAL reports officers found 58-year-old James R. Conaway of Genoa asleep behind the wheel of the truck. According to information filed in McHenry County court, Conaway was charged with aggravated DUI, and a judge cited Conaway's history of alcoholism, when he denied Conaway's pretrial release from county jail.

On November 12th, McHenry Police received a call that a truck hit a curb and a sign. SHAW LOCAL reports officers found 58-year-old James R. Conaway of Genoa asleep behind the wheel of the truck. According to information filed in McHenry County court, Conaway was charged with aggravated DUI, and a judge cited Conaway's history of alcoholism when he denied Conaway's pretrial release from county jail.

Get ready for a Christmas classic like you've never seen it before! Ebenezer Scrooge's Big Genoa Christmas Show transforms Dickens' timeless tale into a hilarious, music-filled celebration of community and holiday spirit, set right here at the Genoa Civic Theatre.Written by Gordon Greenberg and directed by Jeremiah Tudor, this gut-busting, family-friendly production weaves local Genoa touches, familiar faces, and festive fun into a night you won't want to miss.Catch Ebenezer Scrooge's Big Genoa Christmas Show live on December 5, 2025, from 7:30–9:30 PM at the Genoa Civic Theatre.Get your tickets here: genoacivictheatre.com/event-details/ebenezer-scrooges-big-genoa-christmas-show-12-07-2025

Au sommaire de Radio Foot Internationale, ce lundi 10 novembre 2025 (16h10 & 21h10 TU) : Liga, le Barça revient ; Serie A, le Napoli stoppé par Bologne, l'AC Milan freiné à Parme, la Roma de Gasperini et l'Inter en profitent pour se hisser en tête ; Platini : « Coups francs, bouclettes et petit short ». Liga, le Barça revient. Toujours sur le fil défensivement, les Blaugranas sont allés chercher une victoire importante sur le terrain du Celta Vigo (4-2). Yamal buteur, retour gagnant de Lewandowski avec un triplé, pour sa première titularisation depuis un mois. Défense fragile, attaque moins efficace ? Le Real Madrid et ses limites. Atone dans le derby contre le Rayo Vallecano, Mbappé muet, fin de série pour le Kyks, qui n'a pas eu de ballons à exploiter. Catalans et Merengues, animateurs habituels du championnat à la mécanique enrayée. L'Atlético sous pavillon américain. Le fonds d'investissement Apollo Sports Capital devient le nouvel actionnaire majoritaire du club. Les Colchoneros entrent dans une nouvelle dimension financière, des ambitions sportives redéfinies ? Serie A, le Napoli stoppé par Bologne, l'AC Milan freiné à Parme, la Roma de Gasperini et l'Inter en profitent pour se hisser en tête. Deuxième saison d'Antonio Conte sous le Vésuve, l'agacement de l'ex de l'Inter et de la Juve est perceptible, surtout après la claque reçue à Eindhoven en C1. Il exhorte ses joueurs à retrouver l'état d'esprit de la saison passée. Par ici la sortie : Vieira remercié par le Genoa, l'Atalanta se sépare de Juric. La Dea, place forte du championnat, végète à la 13e place. Platini : « Coups francs, bouclettes et petit short ». C'est le titre du livre publié par So Foot et les éditions Marabout, sur un autre « 10 » de légende, à l'occasion des 70 ans du milieu de terrain. Retour sur la carrière de l'ex-capitaine des bleus, et élégant joueur de la Juve. Le foot aux footballeurs aussi. Platoche nourrit le projet d'un musée du foot ouvrier à Jœuf, sa ville natale. Pour débattre avec Annie Gasnier : Chérif Ghemmour, Étienne Moatti et Éric Rabesandratana. Technique/Réalisation : Laurent Salerno --  David Fintzel/Pierre Guérin.

Au sommaire de Radio Foot Internationale, ce lundi 10 novembre 2025 (16h10 & 21h10 TU) : Liga, le Barça revient ; Serie A, le Napoli stoppé par Bologne, l'AC Milan freiné à Parme, la Roma de Gasperini et l'Inter en profitent pour se hisser en tête ; Platini : « Coups francs, bouclettes et petit short ». Liga, le Barça revient. Toujours sur le fil défensivement, les Blaugranas sont allés chercher une victoire importante sur le terrain du Celta Vigo (4-2). Yamal buteur, retour gagnant de Lewandowski avec un triplé, pour sa première titularisation depuis un mois. Défense fragile, attaque moins efficace ? Le Real Madrid et ses limites. Atone dans le derby contre le Rayo Vallecano, Mbappé muet, fin de série pour le Kyks, qui n'a pas eu de ballons à exploiter. Catalans et Merengues, animateurs habituels du championnat à la mécanique enrayée. L'Atlético sous pavillon américain. Le fonds d'investissement Apollo Sports Capital devient le nouvel actionnaire majoritaire du club. Les Colchoneros entrent dans une nouvelle dimension financière, des ambitions sportives redéfinies ? Serie A, le Napoli stoppé par Bologne, l'AC Milan freiné à Parme, la Roma de Gasperini et l'Inter en profitent pour se hisser en tête. Deuxième saison d'Antonio Conte sous le Vésuve, l'agacement de l'ex de l'Inter et de la Juve est perceptible, surtout après la claque reçue à Eindhoven en C1. Il exhorte ses joueurs à retrouver l'état d'esprit de la saison passée. Par ici la sortie : Vieira remercié par le Genoa, l'Atalanta se sépare de Juric. La Dea, place forte du championnat, végète à la 13e place. Platini : « Coups francs, bouclettes et petit short ». C'est le titre du livre publié par So Foot et les éditions Marabout, sur un autre « 10 » de légende, à l'occasion des 70 ans du milieu de terrain. Retour sur la carrière de l'ex-capitaine des bleus, et élégant joueur de la Juve. Le foot aux footballeurs aussi. Platoche nourrit le projet d'un musée du foot ouvrier à Jœuf, sa ville natale. Pour débattre avec Annie Gasnier : Chérif Ghemmour, Étienne Moatti et Éric Rabesandratana. Technique/Réalisation : Laurent Salerno --  David Fintzel/Pierre Guérin.

New Noah revealed… and he's having an affair with Sienna! Claire goes all the way with Holden… and back… to Kyle! Visit https://www.yrchat.com to chat with fun and friendly fans of The Young and the Restless. THIS WEEK: Ali’s Y&R Recap, The Weekly Y&R Polls, a “Who Said It” Quote Game, and Opening “The Chatterbox” […]

Commentiamo la bella vittoria dell'Atalanta contro l'Olympique Marsiglia, la Juventus che prende forma, un'Inter nervosetta e due cambi di panchina. Learn more about your ad choices. Visit megaphone.fm/adchoices

Purgatory is not punishment. It's purification. In this episode, we explore the mystical heart of the Church's teaching on purgatory through the lens of love, unveiling, and divine transformation. Drawing on the Catechism, the early Fathers, and the voices of the mystics: St. Catherine of Genoa, St. John of the Cross, St. Thérèse of Lisieux, Julian of Norwich, and others—this reflection looks beyond fire and fear to reveal purgatory as the soul's unveiling before God.We'll uncover what the Catholic Church actually teaches about purgatory, what belongs to private revelation and opinion, and how the saints understood purification as the fire of divine love rather than punishment. Through this lens, purgatory becomes the final movement of theosis, the soul's slow adaptation to eternal light—the moment the veil begins to fall.

https://amzn.to/430RirJ GET YOUR COPY of F&F TODAY! AUDIOBOOK • EBOOK • PAPERBACK Available on Amazon & Everywhere Books Are Sold Signed editions and digital extras at https://www.RestlessForest.com Join me for the discussion: YouTube: https://www.youtube.com/@RestlessForestBooks Facebook: https://www.facebook.com/groups/restlessforestbooks Thank you for your support. … And now Y&R Chat: Claire and Holden get freaky!; Matt Clark is back?!; […]

A weary King Kull gazes into the forbidden mirrors of Tuzun Thune, seeking wisdom beyond mortal grasp. But in those shifting reflections lies a peril far greater than any enemy he's ever faced. The Mirrors of Tuzun Thune by Robert E. Howard. That's next on The Lost Sci-Fi Podcast.Quick heads-up: our brand-new Lost Sci-Fi Weekly newsletter launches this Monday, October 27. Tap the link in the description or visit LostSciFi.com to get it first.Newsletter - https://lostscifi.com/freeBefore there was Conan, there was King Kull—a brooding, introspective warrior-king from the ancient, drowned kingdom of Valusia. Created by Robert E. Howard, Kull first appeared in The Shadow Kingdom in 1929, one of the earliest true “sword and sorcery” tales.Howard wrote only a handful of complete Kull stories, but they stand among his most thoughtful and dreamlike works. The best known are The Shadow Kingdom, Kings of the Night, and today's story, The Mirrors of Tuzun Thune—a haunting story about the peril of looking too deeply into one's own reflection.You might remember the 1997 movie Kull the Conqueror — starring Kevin Sorbo (of Hercules fame) — which is the only movie explicitly featuring Kull. It was supposed to be a Conan the Barbarian sequel but was reworked into a Kull story when rights issues arose.We will find our story on page 367 in Weird Tales magazine in September 1929, The Mirrors of Tuzun Thune by Robert E. Howard…Next on The Lost Sci-Fi Podcast, A proud young exile meets a storm-working dwarf on a desolate Genoa shore — and in a single Faust-like bargain barters more than he understands. A metamorphosis so literal and so damning it cannot be untold. Or forgotten! Transformation by Mary Shelley.Rise - http://bit.ly/45So7Yr☕ Buy Me a Coffee https://www.buymeacoffee.com/scottsVDiscord - https://discord.gg/EXrY7UHTFacebook - https://www.facebook.com/TheLostSciFiPodcastTwitter - https://x.com/LostSciFiPodInstagram - https://www.instagram.com/lostscifiguy❤️ ❤️ Thanks to All Our Listeners Who Bought Us a Coffee$200 Someone$100 Tony from the Future$75 James Van Maanenberg$50 MizzBassie, Anonymous Listener$25 Someone, Eaten by a Grue, Jeff Lussenden, Fred Sieber, Anne, Craig Hamilton, Dave Wiseman, Bromite Thrip, Marwin de Haan, Future Space Engineer, Fressie, Kevin Eckert, Stephen Kagan, James Van Maanenberg, Irma Stolfo, Josh Jennings, Leber8tr, Conrad Chaffee, Anonymous Listener$15 Every Month Someone$15 Someone, Carolyn Guthleben, Patrick McLendon, Curious Jon, Buz C., Fressie, Anonymous Listener$10 Anonymous Listener$5 Every Month Eaten by a Grue$5 Denis Kalinin, Timothy Buckley, Andre'a, Martin Brown, Ron McFarlan, Tif Love, Chrystene, Richard Hoffman, Anonymous ListenerPlease participate in our podcast survey https://podcastsurvey.typeform.com/to/gNLcxQlk Hosted on Acast. See acast.com/privacy for more information.